APA (7th ed.) Citation

J, C., S, L., & SY, L. (2026). Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study. Thoracic cancer, 17(18), e70389. https://doi.org/10.1111/1759-7714.70389

Chicago Style (17th ed.) Citation

J, Choi, Lee S, and Lee SY. "Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study." Thoracic Cancer 17, no. 18 (2026): e70389. https://doi.org/10.1111/1759-7714.70389.

MLA (9th ed.) Citation

J, Choi, et al. "Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study." Thoracic Cancer, vol. 17, no. 18, 2026, p. e70389, https://doi.org/10.1111/1759-7714.70389.